Dihydro-CDDO-trifluoroethyl amide (dh404), a rodent-tolerable bardoxolone methyl analog, significantly reduced proteinuria-induced tubular cell mitochondrial damage in a model of diabetic kidney disease.
- Treatment with bardoxolone methyl analog improved mitochondrial function, suppressed inflammatory signaling, and reduced oxidative stress.
- Treatment with bardoxolone methyl analog was protective of the renal tubular interstitium, decreased fibrosis, and preserved kidney function despite not improving proteinuria.
Disclaimer
Bardoxolone methyl and omaveloxolone are investigational drugs. Safety and efficacy have not been established by any agency.